Desvenlafaxine

{{Short description|SNRI antidepressant}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Infobox drug | Verifiedfields = changed | Watchedfields = changed | class = Serotonin–norepinephrine reuptake inhibitor (SNRI) | verifiedrevid = 443583795 | image = Desvenlafaxine stereoisomers labelled.svg | image_class = skin-invert-image | width = 250 | alt = Skeletal formula | image2 = Desvenlafaxine stereoisomers ball-and-stick models from xtal.png | image_class2 = bg-transparent | alt2 = Ball-and-stick model of desvenlafaxine

| pronounce = {{IPAc-en|d|ɛ|s|ˌ|v|ɛ|n|l|ə|ˈ|f|æ|k|s|iː|n}} {{respell|des|ven|lə|FAK|seen}} | tradename = Pristiq, Desfax, Ellefore, others | Drugs.com = {{drugs.com|monograph|desvenlafaxine-succinate}} | MedlinePlus = a608022 | DailyMedID = Desvenlafaxine | pregnancy_AU = B2 | routes_of_administration = By mouth | ATC_prefix = N06 | ATC_suffix = AX23 | legal_AU = S4 | legal_CA = Rx-only | legal_CA_comment = <ref>{{cite web | title=Mental health | website=Health Canada | date=9 May 2018 | url=https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/mental-health.html | access-date=13 April 2024}}</ref> | legal_US = Rx-only | legal_BR = C1 | legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=Diário Oficial da União |language=pt-BR |publication-date=2023-04-04}}</ref>

| bioavailability = 80% | protein_bound = Low (30%) | metabolism = CYP2C19,<ref>{{cite web |title=Desvenlafaxine Metabolic pathways |url=https://smpdb.ca/view/SMP0000636?highlight[compounds][]=DB06700&highlight[proteins][]=DB06700 |website=SMPBD |access-date=February 3, 2022}}</ref> CYP3A4, (CYP2D6 is not involved) | elimination_half-life = 11 hours | excretion = 45% excreted unchanged in urine

| IUPHAR_ligand = 7158 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 93413-62-8 | PubChem = 125017 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB06700 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 111300 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = NG99554ANW | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D07793 | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 83527 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1118 | synonyms = ''O''-desmethylvenlafaxine, WY-45233

| IUPAC_name = (''RS'')-4-[2-dimethylamino-1-(1-hydroxycyclohexyl) ethyl]phenol | C = 16 | H = 25 | N = 1 | O = 2 | smiles = OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC2 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = KYYIDSXMWOZKMP-UHFFFAOYSA-N }}  '''Desvenlafaxine''', sold under the brand name '''Pristiq''' among others, is a medication used to treat major depressive disorder.<ref name=AHFS2019/> It is an antidepressant of the serotonin–norepinephrine reuptake inhibitor (SNRI) class and is taken by mouth.<ref name=AHFS2019>{{cite web |title=Desvenlafaxine Succinate Monograph for Professionals |url=https://www.drugs.com/monograph/desvenlafaxine-succinate.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=18 March 2019 |language=en}}</ref> It is recommended that the need for further treatment be occasionally reassessed.<ref name=AHFS2019/> Studies have shown similar effectiveness compared to its parent compound venlafaxine.<ref name=":0">{{cite journal | vauthors = Coleman KA, Xavier VY, Palmer TL, Meaney JV, Radalj LM, Canny LM | title = An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator | journal = CNS Spectrums | volume = 17 | issue = 3 | pages = 131–141 | date = September 2012 | pmid = 22883424 | doi = 10.1017/S1092852912000648 | s2cid = 35165334 }}</ref><ref name= "Ottawa">Poitras V, Visintini S. Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Oct 25. Key Findings. https://www.ncbi.nlm.nih.gov/books/NBK507131/</ref>

Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems.<ref name=AHFS2019/> In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that desvenlafaxine's product labeling warn of this risk.<ref name="Healy2022" /><ref name="PRAC2019" /> Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.<ref name=AHFS2019/>

Desvenlafaxine was approved for medical use in the United States in 2008.<ref name=AHFS2019/> In Europe its application for use was denied in 2009, although has since been approved for Spain and Germany.<ref name=EMA2009/> In 2023, it was the 189th most commonly prescribed medication in the United States, with more than 2{{nbsp}}million prescriptions.<ref name="Top 300">{{cite web | title=Top 300 of 2023 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=12 August 2025 | archive-date=12 August 2025 | archive-url=https://web.archive.org/web/20250812130026/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Desvenlafaxine Drug Usage Statistics, United States, 2014 - 2023 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Desvenlafaxine | access-date = 20 August 2025 }}</ref>

==Medical uses== Desvenlafaxine is primarily used as a treatment for major depressive disorder.<ref name = TGA>{{cite web|title=PRODUCT INFORMATION – PRISTIQ desvenlafaxine (as succinate)|website=TGA eBusiness Services|publisher=Pfizer Australia Pty Ltd|date=10 December 2012|access-date=8 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06360-3|format=PDF}}</ref> Use has only been studied up to 8 weeks.<ref name=AHFS2019/> Multiple studies have shown comparable effectiveness to venlafaxine as well as a lower rate of nausea.<ref name=":0" /><ref name= "Ottawa"/> Other studies have shown it to be either less effective<ref name=EMA2009>{{cite web |title=Withdrawal Assessment Report for Dessvenlafaxime |url=https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ellefore_en.pdf |website=EMA |access-date=22 March 2019 |page=3}}</ref> or more effective<ref>{{cite journal | vauthors = Rejas Gutiérrez J, Blanca Tamayo M, Gascón Barrachina J, Armada Peláez B | title = [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain] | journal = Revista De Psiquiatria Y Salud Mental | volume = 9 | issue = 2 | pages = 87–96 | date = 2016 | pmid = 26475204 | doi = 10.1016/j.rpsm.2015.08.002 }}</ref> than venlafaxine.

Doses of 50 to 400 mg/day appear effective for major depressive disorder, although no additional benefit was demonstrated at doses greater than 50 mg/day, and adverse events and discontinuations were more frequent at higher doses.<ref>{{cite journal | vauthors = Perry R, Cassagnol M | title = Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder | journal = Clinical Therapeutics | volume = 31 | issue = Pt 1 | pages = 1374–1404 | date = June 2009 | pmid = 19698900 | doi = 10.1016/j.clinthera.2009.07.012 }}</ref>

Desvenlafaxine improves the HAM-D17 score<ref>{{cite journal | vauthors = Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT | title = An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder | journal = CNS Spectrums | volume = 14 | issue = 3 | pages = 144–154 | date = March 2009 | pmid = 19407711 | doi = 10.1017/s1092852900020125 | s2cid = 32901068 }}</ref> and measures of well-being such as the Sheehan Disability Scale (SDS) and 5-item World Health Organization Well-Being Index (WHO-5).<ref>{{cite journal | vauthors = Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ | title = Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials | journal = The Journal of Clinical Psychiatry | volume = 70 | issue = 10 | pages = 1365–1371 | date = October 2009 | pmid = 19906341 | doi = 10.4088/JCP.09m05133blu }}</ref>

Desvenlafaxine may also be prescribed off label for the treatment of hot flashes.<ref>{{cite web | vauthors = Marshall H | title = Pristiq (desvenlafaxine) | url = https://www.medicalnewstoday.com/articles/drugs-pristiq#side-effects | publisher = Medical News Today | access-date = 28 September 2025 }}</ref> A review of studies in 2014 found a 55–69% reduction in number of hot flashes.<ref>{{cite journal | vauthors = Tella S, Gallagher J | title = Efficacy of desvenlafaxine succinate for menopausal hot flashes | journal = Expert Opinion on Pharmacotherapy | volume = 15 | issue = 16 | pages = 2407–2418 | date = Nov 2014 | pmid = 25252697 | doi = 10.1517/14656566.2014.964641 }}</ref>

==Adverse effects== Frequency of adverse effects:<ref name = TGA/><ref name = DM>{{cite web|title=DESVENLAFAXINE tablet, extended release [Ranbaxy Pharmaceuticals Inc.]|website=DailyMed|publisher=Ranbaxy Pharmaceuticals Inc.|date=March 2013|access-date=9 November 2013|url=https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91cf39c9-4d26-480a-a3a3-a3d8d4c4d222}}</ref><ref>{{cite web|title=desvenlafaxine (Rx) - Pristiq, Khedezla|website=Medscape Reference|publisher=WebMD|access-date=9 November 2013|url=http://reference.medscape.com/drug/pristiq-khedezla-desvenlafaxine-342964}}</ref>

'''Very common adverse effects include:''' {{colbegin|colwidth=15em}} *Nausea *Headache *Dizziness *Dry mouth *Hyperhidrosis *Diarrhea *Insomnia *Constipation *Fatigue {{colend}}

'''Common adverse effects include:'''

{{colbegin|colwidth=15em}} *Tremor *Blurred vision *Mydriasis *Decreased appetite *Sexual dysfunction *Insomnia *Anxiety *Elevated cholesterol and triglycerides *Proteinuria *Vertigo *Feeling jittery *Asthenia *Nervousness *Hot flush *Irritability *Abnormal dreams *Urinary hesitation *Yawning *Rash {{colend}}

'''Uncommon adverse effects include:''' {{colbegin|colwidth=15em}} *Hypersensitivity *Syncope *Depersonalization *Hypomania *Withdrawal syndrome *Urinary retention *Epistaxis (nose bleed) *Alopecia (hair loss) *Orthostatic hypotension *Peripheral coldness {{colend}}

'''Rare adverse effects include:''' {{colbegin|colwidth=15em}} *Hyponatraemia (low blood sodium) *Seizures *Extrapyramidal side effects *Hallucinations *Angioedema *Photosensitivity reaction *Stevens–Johnson syndrome {{colend}}

'''Common adverse effects whose intensity is unknown include:''' {{colbegin|colwidth=15em}} *Abnormal bleeding (gastrointestinal bleeds) *Narrow-angle glaucoma *Mania *Interstitial lung disease *Eosinophilic pneumonia *Hypertension *Suicidal behavior and thoughts *Serotonin syndrome {{colend}}

=== Post-SSRI sexual dysfunction === {{Main|Post-SSRI sexual dysfunction}}

Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including desvenlafaxine.<ref name="Bala2018">{{cite journal | vauthors = Bala A, Tue Nguyen HM, Hellstrom WJ | title = Post-SSRI Sexual Dysfunction: A Literature Review | journal = Sexual Medicine Reviews | volume = 6 | issue = 1 | pages = 29–34 | date = January 2018 | pmid = 28778697 | doi = 10.1016/j.sxmr.2017.07.002 }}</ref><ref name="Healy2022">{{cite journal | vauthors = Healy D, Bahrick A, Bak M, Barbato A, Calabro RS, Chubak BM | title = Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin | journal = International Journal of Risk & Safety in Medicine | volume = 33 | issue = 1 | pages = 65–76 | date = 2022 | pmid = 34719438 | pmc = 8925105 | doi = 10.3233/JRS-210023 }}</ref> Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur.<ref name="Healy2022" /> The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment.<ref name="Healy2018">{{cite journal | vauthors = Healy D, Le Noury J, Mangin D | title = Enduring sexual dysfunction after treatment with antidepressants, 5-alpha-reductase inhibitors and isotretinoin: 300 cases | journal = International Journal of Risk & Safety in Medicine | volume = 29 | issue = 3–4 | pages = 125–134 | date = 2018 | pmid = 29733030 | doi = 10.3233/JRS-180744 | pmc = 6004900 }}</ref> The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued.<ref name="Healy2024barriers">{{cite journal | vauthors = Healy D, Mangin D | title = Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence | journal = Epidemiology and Psychiatric Sciences | volume = 33 | article-number = e52 | date = 2024 | pmid = 39363727 | pmc = 11450419 | doi = 10.1017/S2045796024000532 | doi-access = free }}</ref>

As the primary active metabolite of venlafaxine, desvenlafaxine shares its parent compound's serotonin reuptake inhibiting mechanism, and PSSD has been reported with both drugs.<ref name="Healy2022" /> A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SNRIs, though the actual prevalence remains uncertain and the condition is likely underreported.<ref name="BenSheetrit2023">{{cite journal | vauthors = Ben-Sheetrit J, Aizenberg D, Csoka AB, Weizman A, Hermesh H | title = Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants | journal = Annals of General Psychiatry | volume = 22 | issue = 1 | article-number = 15 | date = April 2023 | pmid = 37076856 | pmc = 10122283 | doi = 10.1186/s12991-023-00447-0 | doi-access = free }}</ref>

In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that product labels for all SSRIs and SNRIs, including desvenlafaxine, be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped.<ref name="PRAC2019">{{cite web | title = PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting | publisher = European Medicines Agency | date = 11 June 2019 | url = https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-may-2019-prac-meeting_en.pdf | access-date = 8 April 2026 }}</ref> Health Canada followed with similar label updates in 2021.<ref name="Healy2024barriers" /> In 2024, Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information to reflect this risk, noting that desvenlafaxine already carried a warning about persistent sexual dysfunction prior to the alignment.<ref name="TGA2024">{{cite web | title = Updated warnings about persistent sexual dysfunction for antidepressants | publisher = Therapeutic Goods Administration | date = 23 May 2024 | url = https://www.tga.gov.au/news/safety-updates/updated-warnings-about-persistent-sexual-dysfunction-antidepressants | access-date = 8 April 2026 }}</ref>

==Pharmacology== Desvenlafaxine is a synthetic form of the isolated major active metabolite of venlafaxine, and is categorized as a serotonin–norepinephrine reuptake inhibitor (SNRI). When most normal metabolizers take venlafaxine, approximately 70% of the dose is metabolized into desvenlafaxine, so the effects of the two drugs are expected to be very similar.<ref name=Foye2012>{{cite book|title=Foye's Principles of Medicinal Chemistry|year=2012|publisher=Lippincott Williams & Wilkins |isbn=978-1-60913-345-0 |page=609| vauthors = Lemke TL, Williams DA }}</ref> It works by blocking the "reuptake" transporters for key neurotransmitters affecting mood, thereby leaving more active neurotransmitters in the synapse. The neurotransmitters affected are serotonin (5-hydroxytryptamine) and norepinephrine (noradrenaline). It is approximately 10 times more potent at inhibiting serotonin uptake than norepinephrine uptake.<ref name=Deecher2006>{{cite journal | vauthors = Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH | title = Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 318 | issue = 2 | pages = 657–665 | date = August 2006 | pmid = 16675639 | doi = 10.1124/jpet.106.103382 | s2cid = 15063064 }}</ref>

{| class="wikitable" |- ! Transporter !! Ki[nM]<ref name=Deecher2006 /><ref>{{cite web|title=PDSP Ki Database |website=Psychoactive Drug Screening Program (PDSP) |author1-link=Bryan Roth | vauthors = Roth BL, Driscol J |url=https://pdsp.unc.edu/databases/pdsp.php?recDDRadio=recDDRadio&receptorDD=&receptor=&speciesDDRadio=speciesDDRadio&speciesDD=&species=&sourceDDRadio=sourceDDRadio&sourcesDD=&source=&hotDDRadio=hotDDRadio&hotLigandDD=&hotLigand=&testDDRadio=testDDRadio&testLigandDD=8475&testLigand=&refDDRadio=refDDRadio&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query |publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |access-date=7 July 2018 |date=Dec 2012 }}</ref> !IC50 [nM]<ref name=Deecher2006 /> |- | SERT || 40.2 || 47.3 |- | NET || 558.4 || 531.3 |}

==Society and culture==

=== Legal status ===

==== United States ==== [[File:Pristiq pills.jpg|thumb|right|250px|Pristiq 50 mg tablets (US)]] Wyeth announced on 23 January 2007 that it received an approvable letter from the Food and Drug Administration for desvenlafaxine. Final approval to sell the drug was contingent on a number of things, including: *A satisfactory FDA inspection of Wyeth's Guayama, Puerto Rico facility, where the drug is to be manufactured; *Several postmarketing surveillance commitments, and follow-up studies on low-dose use, relapse, and use in children; *Clarity by Wyeth around the company's product education plan for physicians and patients; *Approval of desvenlafaxine's proprietary name, Pristiq.<ref>{{cite press release |url = http://www.biospace.com/news_story.aspx?StoryID=43424&full=1 |title = Wyeth Receives Approvable Letter From FDA For Pristiq (Desvenlafaxine Succinate) For The Treatment Of Major Depressive Disorder |date = 2007-01-23 |access-date = 2007-04-04 |archive-date = 2007-02-21 |archive-url = https://web.archive.org/web/20070221003600/http://www.biospace.com/news_story.aspx?StoryID=43424&full=1 }}</ref>

The FDA approved the drug for antidepressant use in February 2008, and was to be available in US pharmacies in May 2008.<ref>{{cite press release |url = http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2008/1204331198948.html |title = FDA Approves Pristiq |date = 2008-02-29 |publisher = Wyeth |access-date = 2008-02-29 |archive-url = https://web.archive.org/web/20080305175615/http://www.wyeth.com/news?nav=display&navTo=%2Fwyeth_html%2Fhome%2Fnews%2Fpressreleases%2F2008%2F1204331198948.html |archive-date = 2008-03-05 }}</ref>

In March 2017, the generic form of the drug was made available in the US.{{cn|date=February 2024}}

==== Canada ==== On February 4, 2009, Health Canada approved use of desvenlafaxine for treatment of depression.<ref>[http://205.193.93.51/NocWeb/viewnoce.jsp?noc=cigci Health Canada Notice of Compliance - Pristiq]{{Dead link|date=July 2019 |bot=InternetArchiveBot |fix-attempted=yes }}. February 4, 2009, retrieved on March 9, 2009.</ref><ref>{{cite web|url=http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2009_pristiq_115439-eng.php|title=Summary Basis of Decision (SBD) PrPristiq|date=2009-05-29|publisher=Health Canada|access-date=2016-12-30|archive-url=https://web.archive.org/web/20161018124531/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2009_pristiq_115439-eng.php|archive-date=2016-10-18}}</ref>

==== European Union ==== In 2009, an application to market desvenlafaxine for major depressive disorder in the European Union was declined.<ref name=EMA2009/> In 2012, Pfizer received authorization in Spain to market desvenlafaxine for the disorder.<ref>{{cite web|url=http://www.aemps.gob.es/cima/especialidad.do?metodo=verPresentaciones&codigo=75561 |title=Pristiq 100 mg Comprimidos de Liberacion Prolongada |publisher=AEMPS Medicines Online Information Center - CIMA |access-date=2016-12-30}}</ref><ref>{{cite web |url= http://www.aemps.gob.es/cima/especialidad.do?metodo=verPresentaciones&codigo=75560 |title=Pristiq 50 mg Comprimidos de Liberacion Prolongada |publisher= AEMPS Medicines Online Information Center - CIMA |access-date=2016-12-30}}</ref> In August 2022, following a 14-year approval process, desvenlafaxine was brought to the market for the disorder in Germany.<ref>{{Cite web | vauthors = Möthrath C |title= Desvenlafaxin: Grünes Licht nach 14 Jahren |url=https://www.apotheke-adhoc.de/nachrichten/detail/pharmazie/desvenlafaxin-gruenes-licht-nach-14-jahren/ | date=August 1, 2022|access-date=2022-08-12 |website=Apotheke Adhoc |language=de-DE}}</ref> Desvenlaflaxine has been available in Italy since 2022.

==== Australia ==== Desvenlafaxine is classified as a schedule 4 (prescription only) drug in Australia. It was listed on the Pharmaceutical Benefits Scheme in 2008 for the treatment of major depressive disorders.<ref name="PBS">{{cite web | url = https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-11/pbac-psd-desvenlafaxine-nov08 | title = Desvenlafaxine succinate, tablet, (extended release), 50 mg and 100 mg (base), Pristiq®, November 2008 | date = | website = Pharmaceutical Benefits Scheme (PBS) | publisher = | quote = }}</ref>

== See also == * List of antidepressants

== References == {{Reflist}}

Category:Serotonin–norepinephrine reuptake inhibitors Category:Cyclohexanols Category:Dimethylamino compounds Category:Phenethylamines Category:4-Hydroxyphenyl compounds Category:Drugs developed by Wyeth Category:Drugs developed by Pfizer Category:Tertiary alcohols Category:Human drug metabolites Category:Wikipedia medicine articles ready to translate Category:Antidepressants